Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

Overview of attention for article published in Blood Cancer Discovery, July 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#10 of 166)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

So far, Altmetric has seen 12 news stories from 12 outlets.

Treatment with ficlatuzumab (previously AV-299) and cytarabine resulted in promising clinical activity in a population of…

July 22, 2021 2 min read Source/Disclosures Published by: Source: Wang VE, et al.

NEW YORK (Reuters) – The combination of ficlatuzumab plus chemotherapy showed considerable early promise in relapsed/refractory…

The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 8 additional news stories.